FDA Approves AstraZeneca’s Perioperative Imfinzi Regimen for Bladder Cancer
AstraZeneca says Imfinzi with neoadjuvant enfortumab vedotin was approved in the US for patients with muscle-invasive bladder cancer.
Related stories
Alberta Expects Immediate Oil Sands Investment After Royalty Changes
Alberta's finance minister says the province expects oil sands investment immediately following changes to its royalty regime.
M impact | REGULATION | Nov 13, 2026, 09:28 PM UTC
Nasdaq Issues CN Healthy Food Tech Group Delisting Determination
Nasdaq issued an additional delisting determination under Listing Rule 5101 and the Misrepresentation Rules, based on information from the CSRC concerning the company’s filings, su
M impact | REGULATION | Nov 13, 2026, 09:23 PM UTC
CN Healthy Food Tech Faces Additional Nasdaq Delisting Determination
Nasdaq issued an additional delisting determination for CN Healthy Food Tech over CSRC allegations.
M impact | REGULATION | Nov 13, 2026, 09:19 PM UTC
NYSE Regulation Begins Delisting Proceedings for PSQ Holdings Stock
NYSE Regulation notified PSQ Holdings on November 9, 2026, that it would begin delisting proceedings after the company failed to meet the $15 million average global market capitali
M impact | REGULATION | Nov 13, 2026, 09:17 PM UTC
Soros Fund Management LLC raises its share stake in Micron Technology by 58.9% to 35,618 shares - SEC filing, and raises its share stake in Intel to 2.8 million shares $INTC $MSCI
L impact | REGULATION | Nov 13, 2026, 09:16 PM UTC
Nasdaq Panel Denies NextNRG’s Listing Appeal
Nasdaq’s Hearings Panel denied NextNRG’s request to continue its listing after the company failed to meet the $1.00 minimum bid price and $35 million market value requirements. The
M impact | REGULATION | Nov 13, 2026, 09:15 PM UTC